- Home
- CINT vs CATX Comparison
CINT vs CATX Comparison
Compare CINT & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CINT | CATX |
|---|---|---|
| Founded | 1995 | 1983 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 704.9M | 569.6M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CINT | CATX |
|---|---|---|
| Price | $5.07 | $4.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $7.02 | ★ $12.11 |
| AVG Volume (30 Days) | 93.1K | ★ 1.3M |
| Earning Date | 03-11-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.86 | $12.71 |
| Revenue Next Year | $11.23 | N/A |
| P/E Ratio | $17.94 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.98 | $1.60 |
| 52 Week High | $6.71 | $6.16 |
Technical Indicators
Market Signals| Indicator | CINT | CATX |
|---|---|---|
| Relative Strength Index (RSI) | 49.75 | 41.73 |
| Support Level | $4.93 | $3.24 |
| Resistance Level | $5.51 | $4.54 |
| Average True Range (ATR) | 0.25 | 0.35 |
| MACD | -0.04 | -0.13 |
| Stochastic Oscillator | 35.04 | 21.27 |
Price Performance
Historical ComparisonAbout CINT CI&T Inc
CI&T Inc is engaged in providing plans, design, and software engineering services to enable digital transformation for companies. The company mainly develops customizable software through the implementation of several software solutions, including Machine Learning, Artificial Intelligence (AI), Analytics, Cloud, and Mobility technologies. The majority of the revenue is generated from the North America and Europe, followed by Asia, Pacific and Japan.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.